

ANLBIO signs an agreement with Biovian for process development and manufacturing of Adeno Associated Virus-based product, ANL-101, for treatment of Alzheimer's disease.

ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO's proprietary gene therapy vector, ANL-101, followed by 200 L scale production. This Adeno Associated Virus (AAV)-based product is prepared to be evaluated in clinical trials for the treatment of Alzheimer's disease.

In detail, the agreement covers the GMP Cell Bank manufacturing, process and analytical development, and validation of product-specific analytical methods. The manufacturing part of the agreement covers upscaling of the process to working volume of hundreds of liters and subsequent drug product manufacture at Biovian's facilities in Turku, Finland.

ANLBIO, headquartered in Suwon, South Korea, uses its proprietary AAV vector platform as a delivery vehicle for its innovative microRNA-based gene therapy for neurodegenerative diseases including Alzheimer's disease and Huntington's disease. MicroRNAs are small non-coding RNAs that regulate cellular protein levels by inhibiting translation. Dysregulated microRNAs are recognized in Alzheimer's disease. As microRNAs regulate multiple targets and maintain cellular equilibrium of gene expression, the mechanism of ANLBIO's ANL-101 is "restoring the lost equilibrium of gene expression in Alzheimer's brain" by targeting dysregulated microRNAs. The treatment has been shown to reduce neuroinflammation, improve cellular metabolism and cognitive impairment in animal models.

Hong Sung Moon, CEO of ANLBIO

We are very pleased that we have found a CDMO partner that can help us take this important project to the next level. Alzheimer's disease is the most common cause of dementia. As the size of the population age 65 and older continues to increase, the number of people with Alzheimer's or other dementias are growing. ANLBIO wants to address this need through the development and commercialization of innovative delivery platforms such as ANL-101.

Antti Nieminen, CEO of Biovian

We are delighted that ANLBIO has selected us as a partner for the process development and manufacturing of their AAV-based innovative drug candidate. Biovian has about two-decade-long history in developing and manufacturing viral vector processes, and we are happy to have a role in the journey of this novel molecule that holds the potential to help patients with Alzheimer's disease. Thanks to MedClarix Inc, bio-consultancy for bringing Biovian and ANLBIO together.

About ANLBIO

ANLBIO is a South Korean biotech company developing innovative microRNA-based gene therapies for neurodegenerative diseases using its proprietary AAV (Adeno-associated virus) vector platform as a delivering vehicle. Additional information is available at <http://www.anlbio.com/>

About Biovian

Biovian is a Contract Development and Manufacturing Organization, CDMO, that provides One-Stop-Shop services to biotech companies developing innovative gene therapies or biopharmaceuticals. Additional information is available at <https://biovian.com/>

About MedClaris

MedClaris Inc. is a South Korean company offering business development services, regulatory support, and technology evaluation of investment targets in the fields of health care and medicine. The company supports bio-venture companies with early stages in CMC including assisted and networked entry to South Korean markets.